Prospective Observational Study of Pain Evolution in Patients With Primary Knee Osteoarthritis Treated With Pronolis® HD
NO-DOLOR
Estudio Observacional Del Seguimiento Prospectivo de la evolución Del Dolor en Pacientes Con Artrosis Primaria de Rodilla Tratados Con Pronolis® HD
1 other identifier
observational
188
1 country
1
Brief Summary
Prospective observational study of 6 months of follow-up, of national and multicenter scope with medical device with CE marking and according to the usual clinical practice. In addition, due to the observational design of the clinical investigation, no assignment of the patients will be made to any specific study group, but will be carried out in accordance with the usual clinical practice, not applying any intervention other than the usual one in this type of care practice and always in accordance with current clinical guidelines and recommendations and with the indications authorized in Spain. Patients will be recruited by specialists and will be followed for 6 months under the conditions of usual clinical practice.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 21, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 21, 2019
CompletedFirst Submitted
Initial submission to the registry
December 11, 2019
CompletedFirst Posted
Study publicly available on registry
December 12, 2019
CompletedFebruary 21, 2021
December 1, 2019
1.7 years
December 11, 2019
February 18, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
evolution of pain in patients diagnosed with primary knee osteoarthritis 3 months after being treated with hyaluronic acid
3-month baseline change in the domain A score of the WOMAC questionnaire pain will be analyzed to evaluate pain evolution.
3 months
Secondary Outcomes (8)
evolution of pain in patients diagnosed with primary knee osteoarthritis during the study
15 days, 1 and 6 months
Pain evolution in motion
15 days, 1, 3 and 6 months
stiffness evolution
15 days, 1, 3 and 6 months
evolution of the patient's functional capacity
15 days, 1, 3 and 6 months
evolution of the patient's quality of life
3 months
- +3 more secondary outcomes
Eligibility Criteria
The study population will be made up of subjects of legal age diagnosed with primary knee osteoarthritis who have pain equal to or greater than 4 measured by VAS. All patients included in this clinical investigation must have been duly informed by the investigator about the investigation procedure and its objectives.
You may qualify if:
- Patients of both sexes and over 18 years.
- Patients with a previous diagnosis of primary knee osteoarthritis according to ACR criteria and who have a knee x-ray performed during the previous 18 months.
- Patients who attend a control clinic for primary osteoarthritis of symptomatic knee.
- Patients with pain equal to or greater than 4 on the VAS scale.
- Patients who have been prescribed an injection of Pronolis® HD as part of the usual clinical practice.
- Patients who have given their written informed consent to participate in the clinical investigation.
- Patients for whom there is a reasonable expectation of follow-up during the development of clinical research.
- Patients who understand and can complete the questionnaires and do not have cognitive impairment that prevents it.
You may not qualify if:
- Patients with known intolerance to hyaluronic acid.
- Patients with hypersensitivity to intraarticular injections.
- Patients who present with infection in the knee joint.
- Patients presenting with a skin disorder or infection in the area of injection or systemic.
- Coagulation disorders that contraindicate puncture.
- Patients who have been prescribed intra-articular injection in both knees.
- Patients diagnosed with autoimmune rheumatologic diseases or connective diseases.
- Patients diagnosed with microcrystalline diseases.
- Patients with traumatic history in the study joint.
- Patients with a surgical history in the study joint.
- Pregnant or breastfeeding women.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Procare Health Iberia S.L.lead
- Adknoma Health Researchcollaborator
Study Sites (1)
Hospital del Mar
Barcelona, 08003, Spain
Related Publications (1)
Calvet J, Khorsandi D, Tio L, Monfort J. Evaluation of a single-shot of a high-density viscoelastic solution of hyaluronic acid in patients with symptomatic primary knee osteoarthritis: the no-dolor study. BMC Musculoskelet Disord. 2022 May 11;23(1):442. doi: 10.1186/s12891-022-05383-w.
PMID: 35546401DERIVED
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2019
First Posted
December 12, 2019
Study Start
May 28, 2017
Primary Completion
February 21, 2019
Study Completion
October 21, 2019
Last Updated
February 21, 2021
Record last verified: 2019-12